ERYTECH Pharma SA is a late-stage French biopharmaceutical company developing medicinal products for oncology. The company's patented core technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes (eg asparaginase).

ERYTECH's lead product, GRASPA® for treatment of Acute Lymphoblastic Leukemia (ALL), holds orphan designation in Europe and the US. GRASPA® is in pivotal Phase II/III clinical trial and initial sales from early access programs are expected in 2012. ERYTECH has established a cGMP manufacturing facility that will enable it to meet the market for GRASPA® and follow-on products, and the first regional distribution and marketing deal has been signed with Teva Pharmaceuticals.